Series B Raise 2/5/2020 Vena Medical is providing physicians with - - PowerPoint PPT Presentation

Series B Raise

2/5/2020

“Vena Medical is providing physicians with the world’s smallest camera capable of going inside veins and arteries to help them treat stroke.”

Vasc ular Acce ss

Beachhead Market: Ischemic Stroke

795,000 Strokes Annually in the US

• 15 million worldwide

01

$34B Cost to the Healthcare System

• Split between intervention and rehab

02 03

87% Ischemic Stroke

• Clot blocks blood flow to the brain

Current

Pain points

Clot Buster - 3 hour time frame

• Harmful after 3 hours
• 8% of stroke victims
• Does not treat underlying plaque

Stent Retriever - 16 hour time frame

• 25.1%-50% first pass success rate
• $5k-$8k per device
• Visual confirmation necessary
• Trial and Error, Iterative

Aspiration - 16 hour time frame

• 25.1%-50% first pass success rate
• Can cause residual clots when

treating red clots

• Trial and Error, Iterative

https://www.ncbi.nlm.nih.gov/pubmed/29459390

3

Vena Microcatheter

“the imaging catheter”

Vena MicroAngioscope™

“the imaging catheter”

Vena MicroAngioscope

Identify the Best T

• ol

Vascular Access

Verify Position Confirm Retrieval Check Work

• Aspiration better for white

clots

• Stentriever better for red

clots

• Different stentrievers for

different clot compositions

• Real-time deployment
• Verify apposition
• Real-time confirmation of

retrieval

• 8 strokes treated with

100% first pass success

• We can identify and

remove these residual clots

• We can confirm the clot

has been removed before they go on to block smaller arteries

• Physician preference and

best guess

• Expensive escalation

algorithms

• Misdiagnosed

atherosclerotic plaque

• Generic 5 minute rule
• Visual confirmation of

retrieval

• First pass success of 25.1%-

50%

• 18% of cases cause residual

clots

• Contrast from X-ray

pushes clots further

Status Quo: Vena:

Vasc ular Acce ss

Market Overview

240,000 Potential Patient Population

• Annual US Patient Population

01 02 03

$1,200,000,000 Annually

• Estimated Revenue at 100% Market Share

$5000 & Single-use

• Piece price per system, saving hospitals $3500 per procedure

First publication in JNIS

January 2019

Completed Y Combinator

March 2018

First patent filed

August 2017

Completed TMCx

November 2017

First animal study

October 2017

Maria Aboytes comes on board

April 2018

First thrombectomy animal study at Baylor

June 2018

First full-time hire, Director of QA

September 2018

• Dr. Kan invests

July 2018

Completed MassChallenge T exas

August 2018

Broad stroke treatment patent filed

January 2019

Traction

First conference presentation at WLNC

May 2019

FDA Pre-Submission Meeting

April 2019

Moved into the Medical Innovation Xchange

August 2019

Raised our Series A Round

November 2019

IP

Portfolio

The portfolio covers the system as a whole, the optical fiber, the microcatheter, and the balloon catheter individually.

Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021

Path T

• Market

$1.5M

HC First in Man

$1M

V&VT esting

$650k

QMS and Product Dev

$0.5M

25-50 Paid Cases

Seed <$1M Series A <$10M Series B <$20M

First Submission Second Submission

Q2 2021 Q3 2021

10

OUR TEAM

Michael PHILLIPS

Founder

Phil COOPER

Founder

Brandon CARHART

Director of QA

• Dr. Hanna QIN

R&D Scientist

• Dr. Steven COOPER

Primary Medical Advisor

Maria ABOYTES

Advisor / Medina Medical / Inventor of FlowGate

Tasha BOND

Technical Advisor / Former Vention Medical

• Dr. Peter KAN

Chief of Neuro-endovascular Service

Allison KOMIYAMA

Regulatory Specialist

We’ve successfully treated stroke in a pig model using our latest prototype We have an extremely straight forward path to market We have prominent physicians backing

• ur product and helping us develop it

Secured an investment to fund through to commercialization

“Making intravascular procedures faster, easier and safer”

Waterloo, Ontario

+1-506-434-1388

Michael@VenaMed.ca www.venamed.ca